Silence Therapeutics plc is a United Kingdom-based drug development company. The Company is engaged in the development and delivery of ribonucleic acid (RNA) therapeutics. The Company's RNA technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company's technology is in the clinic and has been used in Phase II trials. Its gene silencing technology is designed to regulate expression of various genes and the Company has its own delivery systems targeting a range of organs and cell types. Its RNA interference (RNAi) platform is known as AtuRNAi. The Company's delivery systems deliver both short interfering RNA (siRNA) and messenger RNA (mRNA). The Company has a genetic toolkit with its own therapeutic payloads to modulate gene expression up, as well as down in pre-clinical in vivo models.